Since inhibitors of BET proteins, including OTX and structurally similar inhibitors to JQ1, are currently in clinical trials for several cancers, it is more likely that combination of TEM with BET inhibitors can be translated in clinic for NB and other MYC/MYCN-driven cancers therapies. This evidence concerns the gene MYC and cancer.